Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.

[Complex residual tumors after chemotherapy of nonseminomatous germ cell tumors. Laparoscopic management - limits and chances].

Nonseminomatous germ cell tumors: enlarging masses despite chemotherapy.

Decompression of epidural metastases from germ cell tumors with chemotherapy.

Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.

Chemotherapy immediately after surgery for patients with germ cell tumors.

Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.

Clinical stage I nonseminomatous germ cell tumors of testis. Observation vs retroperitoneal lymph node dissection.

Postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors infiltrating the great vessels.

[Diagnosis and treatment of nonseminomatous germ cell tumors].

Vasculogenesis and angiogenesis in nonseminomatous testicular germ cell tumors.

Management of clinical stage I nonseminomatous germ cell tumors.

Management of patients with poor-prognosis nonseminomatous germ cell cancer.

Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors.

Unusually Located Stroke After Chemotherapy in Testicular Germ Cell Tumors.

Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.

Anatomical retroperitoneoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors: initial operative experience.

Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.

Accuracy of preoperative studies in staging nonseminomatous germ cell testicular tumors.

Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors.

Comparison between clinical and pathological staging in low stage nonseminomatous germ cell testicular tumors.

CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?

Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.

Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors.

A third option in the management of patients with clinical stage I nonseminomatous germ cell tumor?

Suggest Documents

[Complex residual tumors after chemotherapy of nonseminomatous germ cell tumors. Laparoscopic management - limits and chances].

Nonseminomatous germ cell tumors: enlarging masses despite chemotherapy.

Decompression of epidural metastases from germ cell tumors with chemotherapy.

Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.

Chemotherapy immediately after surgery for patients with germ cell tumors.

Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.

Clinical stage I nonseminomatous germ cell tumors of testis. Observation vs retroperitoneal lymph node dissection.

Postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors infiltrating the great vessels.

[Diagnosis and treatment of nonseminomatous germ cell tumors].

Vasculogenesis and angiogenesis in nonseminomatous testicular germ cell tumors.

Management of clinical stage I nonseminomatous germ cell tumors.

Management of patients with poor-prognosis nonseminomatous germ cell cancer.

Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors.

Unusually Located Stroke After Chemotherapy in Testicular Germ Cell Tumors.

Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.

Anatomical retroperitoneoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors: initial operative experience.

Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.

Accuracy of preoperative studies in staging nonseminomatous germ cell testicular tumors.

Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors.

Comparison between clinical and pathological staging in low stage nonseminomatous germ cell testicular tumors.

CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?

Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.

Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors.

A third option in the management of patients with clinical stage I nonseminomatous germ cell tumor?

Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.

Recommend Documents

Follow Us